USA Financial Formulas purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 2,127 shares of the life sciences company’s stock, valued at approximately $582,000.
Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Illumina during the second quarter worth about $3,374,423,000. WCM Investment Management LLC raised its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Primecap Management Co. CA purchased a new position in Illumina during the second quarter worth about $617,981,000. Janus Henderson Group PLC boosted its holdings in Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after purchasing an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP boosted its holdings in Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after purchasing an additional 349,536 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Analyst Ratings Changes
ILMN has been the subject of several analyst reports. Barclays increased their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. TD Cowen lifted their price target on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday. Canaccord Genuity Group upped their price objective on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $225.94.
View Our Latest Research Report on ILMN
Insiders Place Their Bets
In other Illumina news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares of the company’s stock, valued at $168,244,440. The trade was a 13.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by insiders.
Illumina Price Performance
Shares of ILMN opened at $262.54 on Friday. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35. The firm’s fifty day simple moving average is $234.53 and its 200-day simple moving average is $186.01. The firm has a market capitalization of $39.64 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 3.72 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.
Illumina Profile
Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.
The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.
Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.
Recommended Stories
- Five stocks we like better than Illumina
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
